Comparison of antibody-scTRAIL Fc fusion proteins with varying valency for EGFR and TRAIL receptors

Abstract Fusion proteins combining TNF-related apoptosis inducing ligand (TRAIL) and antibody building blocks have emerged as a strategy for the targeted treatment of cancer cells. Using a single-chain derivative of homotrimeric TRAIL (scTRAIL), several targeted and non-targeted scTRAIL fusion prote...

Full description

Saved in:
Bibliographic Details
Main Authors: Dennis Michler, Oliver Seifert, Klaus Pfizenmaier, Roland E. Kontermann
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-00476-7
Tags: Add Tag
No Tags, Be the first to tag this record!